Ignite Creation Date:
2024-05-05 @ 9:53 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00005921
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
2000-06-19
Brief Title:
A Study of the Side Effects of L-743872 in Men With Candidal Esophagitis
Sponsor:
Merck Sharp Dohme LLC
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
An Open Serial-Panel Multiple-Dose Study to Investigate the Safety Tolerability and Pharmacokinetics of L-743872 in Patients With Candida Esophagitis
Status:
COMPLETED
Status Verified Date:
2000-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see if it is safe to give L-743872 to men with candidal esophagitis an AIDS-related yeast infection in the esophagus
Detailed Description:
In this open-label study patients receive intravenous L-743872 every 24 hours at one of three dose levels for 14 days Post-study safety evaluations continue for 4 weeks after the final dose Pharmacokinetics and safety measurements are taken throughout the 6-week study
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 007-00 | None | None | None |